Panagora Asset Management Inc. boosted its position in shares of Agenus Inc. (NASDAQ:AGEN – Get Rating) by 157.4% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 746,764 shares of the biotechnology company's stock after buying an additional 456,594 shares during the quarter. Panagora Asset Management Inc. owned approximately 0.28% of Agenus worth $1,837,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. MetLife Investment Management LLC raised its holdings in Agenus by 23.3% during the 1st quarter. MetLife Investment Management LLC now owns 97,735 shares of the biotechnology company's stock valued at $240,000 after buying an additional 18,480 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Agenus during the 1st quarter valued at $71,000. Bank of New York Mellon Corp raised its holdings in Agenus by 3.9% during the 1st quarter. Bank of New York Mellon Corp now owns 767,692 shares of the biotechnology company's stock valued at $1,889,000 after buying an additional 28,600 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in Agenus by 21.9% during the 1st quarter. JPMorgan Chase & Co. now owns 103,704 shares of the biotechnology company's stock valued at $255,000 after buying an additional 18,617 shares during the last quarter. Finally, Bank of Nova Scotia bought a new stake in Agenus during the 1st quarter valued at $31,000. 51.89% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, TheStreet lowered shares of Agenus from a "c-" rating to a "d" rating in a report on Friday, May 27th.

Agenus Trading Up 5.0 %

Agenus (NASDAQ:AGEN – Get Rating) last issued its quarterly earnings data on Tuesday, August 9th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.06. Agenus had a net margin of 3.07% and a return on equity of 11.65%. During the same quarter in the prior year, the company posted ($0.37) EPS. Analysts predict that Agenus Inc. will post -0.7 EPS for the current fiscal year.

Agenus Company Profile

(Get Rating)

Agenus Inc, a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.

See Also

• Get a free copy of the StockNews.com research report on Agenus (AGEN)
• 3 High Margin Chipmakers Bound to Recover
• 3 Solar Stocks That Will Benefit From the Biden Tariff Holiday
• REV Group Has A Deep Moat In The World Of EVs
• Is G-III Apparel Group, Ltd. A Value Trap?
• Bank Of America Sees Upside In These 2 European Alcohol Stocks

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.